Related references
Note: Only part of the references are listed.Systemic administration of monovalent follistatin-like 3-Fc-fusion protein increases muscle mass in mice
Takayuki Ozawa et al.
ISCIENCE (2021)
Proposal for the binding mode of the 23-mer inhibitory peptide to myostatin
Tomo Asari et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2021)
Strategic structure-activity relationship study on a follistatin-derived myostatin inhibitory peptide
Mariko Saitoh et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Recent Applications of Retro-Inverso Peptides
Nunzianna Doti et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Discovery of a follistatin-derived myostatin inhibitory peptide
Mariko Saitoh et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2020)
Enzymatic Stability of Myostatin Inhibitory 16-mer Peptides
Kentaro Takayama et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2020)
Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia
Chiharu Ojima et al.
CANCER SCIENCE (2020)
Functional redundancy of type I and type II receptors in the regulation of skeletal muscle growth by myostatin and activin A
Se-Jin Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Design and synthesis of potent myostatin inhibitory cyclic peptides
Cedric Rentier et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2019)
Chain-Shortened Myostatin Inhibitory Peptides Improve Grip Strength in Mice
Kentaro Takayama et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial
Talia Golan et al.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE (2018)
Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone
Andrea Iskenderian et al.
SKELETAL MUSCLE (2018)
MYOSTATIN INHIBITOR ACE-031 TREATMENT OF AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY: RESULTS OF A RANDOMIZED, PLACEBO- CONTROLLED CLINICAL TRIAL
Craig Campbell et al.
MUSCLE & NERVE (2017)
Structural Basis for the Effective Myostatin Inhibition of the Mouse Myostatin Prodomain-Derived Minimum Peptide
Tomo Asari et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Development of Potent Myostatin Inhibitory Peptides through Hydrophobic Residue-Directed Structural Modification
Kentaro Takayama et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
Downregulation of myostatin pathway in neuromuscular diseases may explain challenges of anti-myostatin therapeutic approaches
Virginie Mariot et al.
NATURE COMMUNICATIONS (2017)
Activin A more prominently regulates muscle mass in primates than does GDF8
Esther Latres et al.
NATURE COMMUNICATIONS (2017)
A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys
Michael St. Andre et al.
SKELETAL MUSCLE (2017)
Effect of N-Terminal Acylation on the Activity of Myostatin Inhibitory Peptides
Kentaro Takayama et al.
CHEMMEDCHEM (2016)
GDF11 Increases with Age and Inhibits Skeletal Muscle Regeneration
Marc A. Egerman et al.
CELL METABOLISM (2015)
Identification of the Minimum Peptide from Mouse Myostatin Prodomain for Human Myostatin Inhibition
Kentaro Takayama et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
The Inhibitory Core of the Myostatin Prodomain: Its Interaction with Both Type I and II Membrane Receptors, and Potential to Treat Muscle Atrophy
Yutaka Ohsawa et al.
PLOS ONE (2015)
Structural studies of the TGF-βs and their receptors - insights into evolution of the TGF-β superfamily
Andrew P. Hinck
FEBS LETTERS (2012)
Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival
Xiaolan Zhou et al.
CELL (2010)
Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry
Chong Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins
Yisrael Sidis et al.
ENDOCRINOLOGY (2006)
Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide
EL Snyder et al.
PLOS BIOLOGY (2004)
Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases
NM Wolfman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Functional improvement of dystrophic muscle by myostatin blockade
S Bogdanovich et al.
NATURE (2002)
Induction of cachexia in mice by systemically administered myostatin
TA Zimmers et al.
SCIENCE (2002)
Regulation of myostatin activity and muscle growth
SJ Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
